Characteristic expression pattern of oxidative stress in livers with cryptogenic hepatocellular carcinoma

Fukushima,Nobuyoshi; Kuromatsu,Ryoko; Akiba,Jun; Ando,Eiji; Takata,Akio; Sumie,Shuji; Nakano,Masahito; Nakamura,Toru; Kawahara,Akihiko; Torimura,Takuji; Nakashima,Osamu; Okuda,Koji; Yano,Hirohisa; Kage,Masayoshi; Kojiro,Masamichi; Sata,Michio

doi:10.3892/etm.2010.132

Characteristic expression pattern of oxidative stress in livers with cryptogenic hepatocellular carcinoma

Authors:
- Nobuyoshi Fukushima
- Ryoko Kuromatsu
- Jun Akiba
- Eiji Ando
- Akio Takata
- Shuji Sumie
- Masahito Nakano
- Toru Nakamura
- Akihiko Kawahara
- Takuji Torimura
- Osamu Nakashima
- Koji Okuda
- Hirohisa Yano
- Masayoshi Kage
- Masamichi Kojiro
- Michio Sata
View Affiliations

Affiliations: Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Fukuoka 830-0011, Japan , Department of Pathology, Kurume University School of Medicine, Kurume 830-0011, Japan, Department of Diagnostic Pathology, Kurume University Hospital, Kurume 830-0011, Japan, Department of Surgery, Kurume University School of Medicine, Kurume 830-0011, Japan
Published online on: July 21, 2010 https://doi.org/10.3892/etm.2010.132
Pages: 809-816

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mechanism responsible for the development of hepatocellular carcinoma (HCC) in the setting of oxidative stress has yet to be clearly defined. We studied the role of oxidative stress in hepatocarcinogenesis in subjects without underlying chronic viral hepatitis. The subjects were 24 patients negative for serum hepatitis B surface antigen and hepatitis C antibody tests, who underwent hepatic resection for HCC (Group N). Subjects were excluded if diagnosed with liver disease predisposing to HCC. Immunohistochemical staining for oxidative stress-related markers was performed on non-cancerous liver regions. Resected liver tissues adjacent to HCC from 24 patients with chronic hepatitis B (Group B) and 21 patients with chronic hepatitis C (Group C) were also examined. The percentage of 8-hydroxydeoxyguanosine-positive hepatocytes in Group N was significantly lower than that in Group B and that in the combined population of Groups B and C. The percentage of the area positive for 4-hydroxynonenal in Group N was significantly higher than that in Groups B or C. Meanwhile, the percentage of the area positive for manganese superoxide dismutase in Group N was not different from that in Groups B and C. In conclusion, the mechanism of hepatocarcinogenesis through oxidative stress for patients without known liver disease predisposing to HCC may differ from that for patients with chronic viral hepatitis.

View Figures

View References

1.	Wong F and Choi T: Primary liver cancer. Asian experience. Surgery of Liver and Biliary Tract. Blumgart LH: Churchill-Livingstone; London: pp. 1135–1151. 1988
2.	The Research Group for Population-based Cancer Resistration in Japan: Cancer incidence and incidence rates in Japan in 1995: estimates based on data from nine population-based cancer registries. Jpn J Clin Oncol. 30:318–321. 2000. View Article : Google Scholar : PubMed/NCBI
3.	Tanaka H and Tsukuma H: Hepatitis C virus. Cancer Surveys: Infections and Human Cancer. Newton R, Beral V, Weiss RA and Tooze J: Cold Spring Harbor Laboratory; New York: pp. 213–235. 1999
4.	Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ and Alter HJ: Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology. 14:969–974. 1991.PubMed/NCBI
5.	Kiyosawa K, Sodeyama T, Tanaka E, et al: Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 12:671–675. 1990. View Article : Google Scholar : PubMed/NCBI
6.	Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM and Lok AS: NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology. 36:1349–1354. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Davila JA, Morgan RO, Shaib Y, McGlynn KA and El-Serag HB: Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 127:1372–1380. 2004. View Article : Google Scholar : PubMed/NCBI
8.	Seeff LB and Hoofnagle JH: Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 25:3771–3777. 2006. View Article : Google Scholar : PubMed/NCBI
9.	Hatanaka K, Kudo M, Fukunaga T, et al: Clinical characteristics of NonBNonC-HCC: Comparison with HBV and HCV related HCC. Intervirology. 50:24–31. 2007. View Article : Google Scholar : PubMed/NCBI
10.	Davila JA, Morgan RO, Shaib Y, McGlynn KA and El-Serag HB: Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut. 54:533–539. 2005. View Article : Google Scholar : PubMed/NCBI
11.	Gerber M, Thung S and Popper H: Pathology of alcoholic liver injury. Update 1981 and problems. New Trends in Hepatology. Oda T and Okuda K: Medical Tokyo Co Ltd; Tokyo: pp. 8–12. 1986
12.	Haddow JE, Palomaki GE, McClain M and Craig W: Hereditary haemochromatosis and hepatocellular carcinoma in males: a strategy for estimating the potential for primary prevention. J Med Screen. 10:11–13. 2003. View Article : Google Scholar
13.	Moucari R, Rautou PE, Cazals-Hatem D, et al: Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut. 57:828–835. 2008. View Article : Google Scholar : PubMed/NCBI
14.	Hashimoto E, Yatsuji S, Kaneda H, et al: The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease. Hepatol Res. 33:72–76. 2005. View Article : Google Scholar : PubMed/NCBI
15.	Sasaki Y: Does oxidative stress participate in the development of hepatocellular carcinoma? J Gastroenterol. 41:1135–1148. 2006. View Article : Google Scholar : PubMed/NCBI
16.	Shibutani S, Takeshita M and Grollman AP: Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG. Nature. 349:431–434. 1991. View Article : Google Scholar : PubMed/NCBI
17.	Hussain SP and Harris CC: Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 58:4023–4037. 1998.
18.	Zhang H, Xu Y, Kamendulis LM and Klaunig JE: Morphological transformation by 8-hydroxy-2′-deoxyguanosine in Syrian hamster embryo (SHE) cells. Toxicol Sci. 56:303–312. 2000.
19.	Nakae D, Kobayashi Y, Akai H, et al: Involvement of 8-hydroxyguanine formation in the initiation of rat liver carcinogenesis by low dose levels of N-nitrosodiethylamine. Cancer Res. 57:1281–1287. 1997.PubMed/NCBI
20.	Kitada T, Seki S, Iwai S, Yamada T, Sakaguchi H and Wakasa K: In situ detection of oxidative DNA damage, 8-hydroxydeoxyguanosine, in chronic human liver disease. J Hepatol. 35:613–618. 2001. View Article : Google Scholar : PubMed/NCBI
21.	Ichiba M, Maeta Y, Mukoyama T, et al: Expression of 8-hydroxy-2′-deoxyguanosine in chronic liver disease and hepatocellular carcinoma. Liver Int. 23:338–345. 2003.
22.	Bartsch H and Nair J: Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. Cancer Detect Prev. 28:385–391. 2004. View Article : Google Scholar : PubMed/NCBI
23.	Hu W, Feng Z, Eveleigh J, et al: The major lipid peroxidation product, trans-4-hydroxy-2-nonenal, preferentially forms DNA adducts at codon 249 of human p53 gene, a unique mutational hotspot in hepatocellular carcinoma. Carcinogenesis. 23:1781–1789. 2002. View Article : Google Scholar
24.	Liu R, Buettner GR and Oberley LW: Oxygen free radicals mediate the induction of manganese superoxide dismutase gene expression by TNF-alpha. Free Radic Biol Med. 28:1197–1205. 2000. View Article : Google Scholar : PubMed/NCBI
25.	Qadri I, Iwahashi M, Capasso JM, et al: Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem J. 378:919–928. 2004. View Article : Google Scholar
26.	Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC and Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:646–649. 1973. View Article : Google Scholar : PubMed/NCBI
27.	Nanashima A, Sumida Y, Morino S, et al: The Japanese integrated staging score using liver damage grade for hepatocellular carcinoma in patients after hepatectomy. Eur J Surg Oncol. 30:765–770. 2004. View Article : Google Scholar
28.	Liver Cancer Study Group of Japan: General Rules for the Clinical and Pathological Study of Primary Liver Cancer. 2nd English edition. Kanehara; Tokyo: 2003
29.	Sobin L and Witteking C: International Union Against Cancer Union TMN Classification of malignant tumors. 5th edition. John Wiley & Sons, Inc; New York: 1997
30.	Desmet VJ, Gerber M, Hoofnagle JH, Manns M and Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology. 19:1513–1520. 1994. View Article : Google Scholar : PubMed/NCBI
31.	Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA and Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 94:2467–2474. 1999. View Article : Google Scholar : PubMed/NCBI
32.	Deugnier YM, Loreal O, Turlin B, et al: Liver pathology in genetic hemochromatosis: a review of 135 homozygous cases and their bioclinical correlations. Gastroenterology. 102:2050–2059. 1992.PubMed/NCBI
33.	Chuma M, Hige S, Nakanishi M, et al: 8-Hydroxy-2′-deoxyguanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 23:1431–1436. 2008.
34.	Tanaka H, Fujita N, Sugimoto R, et al: Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer. 98:580–586. 2008. View Article : Google Scholar : PubMed/NCBI
35.	Matsumoto K, Satoh Y, Sugo H, et al: Immunohistochemical study of the relationship between 8-hydroxy-2′-deoxyguanosine levels in noncancerous region and postoperative recurrence of hepatocellular carcinoma in remnant liver. Hepatol Res. 25:435–441. 2003.
36.	Maki A, Kono H, Gupta M, et al: Predictive power of biomarkers of oxidative stress and inflammation in patients with hepatitis C virus-associated hepatocellular carcinoma. Ann Surg Oncol. 14:1182–1190. 2007. View Article : Google Scholar : PubMed/NCBI
37.	Paradis V, Kollinger M, Fabre M, Holstege A, Poynard T and Bedossa P: In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology. 26:135–142. 1997. View Article : Google Scholar : PubMed/NCBI
38.	Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K and Nakamura H: Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol. 95:1041–1050. 2000. View Article : Google Scholar : PubMed/NCBI
39.	Coleman JD, Prabhu KS, Thompson JT, et al: The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Free Radic Biol Med. 42:1155–1164. 2007. View Article : Google Scholar
40.	Boya P, de la Pena A, Beloqui O, et al: Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J Hepatol. 31:808–814. 1999. View Article : Google Scholar : PubMed/NCBI
41.	Kawaguchi T, Suzuki K, Matsuda Y, et al: Serum-manganesesuperoxide dismutase: normal values and increased levels in patients with acute myocardial infarction and several malignant diseases determined by an enzyme-linked immunosorbent assay using a monoclonal antibody. J Immunol Methods. 127:249–254. 1990. View Article : Google Scholar
42.	Aida Y, Maeyama S, Takakuwa T, et al: Immunohistochemical expression of manganese superoxide dismutase in hepatocellular carcinoma, using a specific monoclonal antibody. J Gastroenterol. 29:443–449. 1994. View Article : Google Scholar
43.	Clemente C, Elba S, Buongiorno G, et al: Manganese superoxide dismutase activity and incidence of hepatocellular carcinoma in patients with Child-Pugh class A liver cirrhosis: a 7-year follow-up study. Liver Int. 27:791–797. 2007.
44.	Sutton A, Nahon P, Pessayre D, et al: Genetic polymorphisms in antioxidant enzymes modulate hepatic iron accumulation and hepatocellular carcinoma development in patients with alcohol-induced cirrhosis. Cancer Res. 66:2844–2852. 2006. View Article : Google Scholar
45.	Ezzikouri S, El Feydi AE, Chafik A, et al: Genetic polymorphism in the manganese superoxide dismutase gene is associated with an increased risk for hepatocellular carcinoma in HCV-infected Moroccan patients. Mutat Res. 649:1–6. 2008. View Article : Google Scholar
46.	Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K and Wakasa K: In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol. 37:56–62. 2002. View Article : Google Scholar : PubMed/NCBI
47.	Toyoda H, Kumada T, Kiriyama S, et al: Characteristics and prognosis of patients in Japan with viral marker-negative hepatocellular carcinoma. J Gastroenterol Hepatol. 23:459–466. 2008. View Article : Google Scholar : PubMed/NCBI
48.	Higashi Y, Tada S, Miyase S, et al: Correlation of clinical characteristics with detection of hepatitis B virus X gene in liver tissue in HBsAg-negative, and HCV-negative hepatocellular carcinoma patients. Liver. 22:374–379. 2002. View Article : Google Scholar
49.	Yokoi Y, Suzuki S, Baba S, Inaba K, Konno H and Nakamura S: Clinicopathological features of hepatocellular carcinomas (HCCs) arising in patients without chronic viral infection or alcohol abuse: a retrospective study of patients undergoing hepatic resection. J Gastroenterol. 40:274–282. 2005. View Article : Google Scholar
50.	Watabe H, Shiratori Y, Tateishi R, et al: Clinical features of patients with HCC who are negative for both HBV and HCV markers. Hepatogastroenterology. 50:2157–2160. 2003.PubMed/NCBI